Examples of HPC plates from four different households showing variable removal depending on the microbial composition of the influent sample. by Hania Zanib (21864477)

Subjects:

Summary of POU UVC LED influent and effluent microbial water quality and log-removals. E. coli was not detected in any influent or effluent samples. Total coliform concentrations s... by Hania Zanib (21864477)

Subjects:

One-Step Synthesis of a Novel Intrinsically Flame-Retardant Thermoplastic Polyamide 6 Elastomer: Structure, Properties, and Spinnability by Haoyi Hu (18980061)

“…Despite great advances in thermoplastic polyamide elastomers (TPAEs), it is still a significant challenge for preparing flame-retardant TPAEs with facile strategies. …”

Prevalence of the common NCD risk factors by region. by Ronald Kusolo (13200268)

Subjects:

Prevalence of the common NCD risk factors by Urbanicity. by Ronald Kusolo (13200268)

Subjects:

Participant characteristics. by Ronald Kusolo (13200268)

Subjects:

SWFT scores and Lactate Levels. by Burhan Demirkıran (21601740)

Subjects:

The weekly content of the 8-week training program. by Burhan Demirkıran (21601740)

Subjects:

HRV Values. by Burhan Demirkıran (21601740)

Subjects:

Changes in subcutaneous fat thickness and muscle mass (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

HRV values (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

Trial Design (Approximately Here). by Burhan Demirkıran (21601740)

Subjects:

Supplementary Figure. by Burhan Demirkıran (21601740)

Subjects:

Biweekly Changes in Body Weight, Body Fat Percentage, Muscle Mass, and BMI During the Retraining Period. by Burhan Demirkıran (21601740)

Subjects:

Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects: